US1011371077 - Common Stock - After market: 45.91 0 (0%)
NYSE:BSX (1/27/2023, 7:04:01 PM)-0.44 (-0.95%)
|GICS Sector||Health Care|
|GICS Industry||Health Care Equipment & Supplies|
|Earnings (Last)||10-26 2022-10-26/bmo||Earnings (Next)||01-31 2023-01-31|
|Ins Owners||0.23%||Inst Owners||91.58%|
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. The company is headquartered in Marlborough, Massachusetts and currently employs 41,000 full-time employees. The Company’s business segments include MedSurg, Rhythm and Neuro, and Cardiovascular. The MedSurg segment includes Endoscopy and Urology and Pelvic Health. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal (GI) and pulmonary conditions. Its Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions. The Rhythm and Neuro segment include Cardiac Rhythm Management (CRM) and Electrophysiology. Its CRM develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment include Interventional Cardiology and Peripheral Interventions. Its Interventional Cardiology develops and manufactures technologies for diagnosing and treating coronary artery disease and structural heart conditions.
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752
CEO: Michael F. Mahoney
The stock market has moved higher in 2023 with some investors appearing to price in a quick drop in inflation in 2023 or an immaculate disinflation scenario. Read more.
/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the...
Here you can normally see the latest stock twits on BSX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.